Janssen Vaccines & Prevention B.v.

Crucell Holland B.v.

University of California

Jehangir Wadia

Robert Anthony Williamson

Gabriel Pascual

Katarina Radosevic

Elissa Keogh

Jaap Goudsmit

Johannes P M Langedijk

Angelique Van 't Wout

Johannes Petrus Langedijk

Steven F Dowdy

Antonietta Impagliazzo

Jan Willem Meijberg

Bryan R Meade

Michelle Wagner

Zhaoqing Ding

Akiko Eguchi

Jan Wilem Meijberg

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to  microtubule-associated protein tau

Provided are influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment comprising the amino acids from position 1 to position x, preferably from position p to position x, of the HA1 domain, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, comprising the amino acids from position y to and including the C-terminal amino acid of the HA1 domain; and (b) an influenza hemagglutinin HA2 domain, wherein the hemagglutinin stem domain polypeptide is resistant to protease cleavage at the junction between HA1 and HA2, and wherein one or more amino acid of the amino acids at positions 337, 340, 352, 353, 402, 406, 409, 413 and/or 416 have been mutated, as compared to the corresponding positions in wild-type influenza HA.

Influenza virus vaccines and uses thereof

The disclosure relates to isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV A and B subtypes, and the use thereof in the diagnosis, prophylaxis, and/or treatment of RSV infections.

Human antibodies binding to RSV G protein

The disclosure provides isolated antibodies and antigen-binding fragments that bind to the G protein of RSV and which are capable of neutralizing RSV.

Human antibodies binding to RSV G proteins

Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.

Anti-human Respiratory Syncytial Virus (RSV) antibodies and methods of use

Anti-human respiratory syncytial virus (RSV) antibodies and methods of use

Antibodies against human respiratory syncytial virus (RSV) and methods of use

The disclosure provides fusion polypeptides and constructs useful in delivering anionically charged nucleic acid molecules including diagnostics and therapeutics to a cell or subject. The fusion constructs include a protein transduction domain and a nucleic acid binding domain, or a protein transduction domain and a nucleic acid that is coated with one or more nucleic acid binding domains sufficient to neutralize an anionic charge on the nucleic acid. Also provided are methods of treating disease and disorders such as cell proliferative disorders.

Transducible delivery of siRNA by dsRNA binding domain fusions to PTD/CPPS

Growing community of inventors

San Diego, CA, United States of America

Jehangir Wadia